The numbers describing India’s biotechnology startup ecosystem are genuinely impressive: growth from roughly 500 ventures in 2018 to over 10,000 by 2025, a bioeconomy contributing nearly 5 per cent of national GDP, and a sustained compound annual growth rate that has attracted serious international attention. What those headline figures obscure is the structural attrition occurring […]
Translational research—the complex, unglamorous work of moving a validated laboratory result through clinical trials, regulatory pathways, manufacturing constraints, and market access barriers—has never been the work of a single institution. It is structurally collaborative by nature, demanding that public funding stability, academic scientific depth, and industrial scaling discipline operate in genuine coordination rather than productive
Translational research occupies the most demanding terrain in the entire innovation landscape. It sits between the clarity of laboratory discovery and the complexity of real-world clinical impact, navigating regulatory pathways, manufacturing constraints, clinical trial design, and reimbursement structures that no single institution—however well-resourced—can manage alone. The history of pharmaceutical and biomedical innovation is littered with
Precision medicine has long promised to match the right treatment to the right patient. CAR-T cell therapy, gene editing, and advanced cell therapies take that promise considerably further—not by targeting symptoms more accurately, but by intervening at the molecular level where disease originates. A patient’s own T cells can be reprogrammed to recognise and destroy
Environmental, social, and governance priorities have undergone a quiet but decisive transformation within India’s biotechnology sector. What began as peripheral reporting obligations and investor relations language has evolved into something far more structurally significant—a framework that is actively shaping how biotech R&D is designed, how biomanufacturing investments are evaluated, and how India’s rapidly expanding bioeconomy
Green by Design: How Esg Is Becoming the Operating Blueprint for India’s Biotech Future Read More »
The pharmaceutical industry’s competitive frontier has quietly shifted. For decades, advantage was defined almost entirely by what happened inside the laboratory—the quality of targets selected, the ingenuity of molecular design, the rigour of preclinical science. Those capabilities remain foundational. What has changed is the weight carried by everything that happens after a molecule is identified:
Traditional drug discovery has operated for decades under an economics model that would be considered untenable in almost any other industry. Pipelines crowded with candidates that fail in late-stage trials, targets pursued on biological intuition rather than rigorous evidence, and chemistry processes that consume years before a molecule reaches its first human test—all sustained by
Drug discovery has historically been an exercise in expensive attrition. The conventional model—identify a disease target, screen compounds, optimise leads, test preclinically, and hope clinical trials vindicate the original hypothesis—is sequential, slow, and brutally uncertain. Candidates fail at every stage, often because the biological target was poorly validated long before a molecule was synthesised. The
For decades, India’s life sciences identity has rested on a formidable but ultimately derivative foundation—generics, contract manufacturing, and vaccine production delivered at a scale and cost efficiency that the world has come to rely upon. That foundation remains commercially indispensable. What is shifting, with gathering momentum, is the ambition layered above it. Biologics and advanced
A decade ago, India’s bioeconomy was valued at $10 billion. Today it stands at $165 billion. The question is no longer whether India can compete globally in biotechnology—it is whether the country can build the institutional architecture to lead it. India’s transformation into a serious biotech contender has unfolded with a speed that has surprised
